IMMUTEP ORD
Weekly Wrap: Shares fall another 2.6% for the week as conflict worsens
ASX 200 slides 2.6% this week to 8,617 as Iran-Israel conflict lifts oil above $100; NST and SYR plunge, while EOS soars on a Middle East contract.
Immutep Discontinues TACTI-004 Phase III Trial Due to Futility
Immutep halts TACTI-004 Phase III in first-line NSCLC due to futility; shares resume trading as cash runway extends beyond Q2 CY2027.
Immutep TACTI-004 NSCLC Trial At 50% Enrolment, Paving Way for Futility Analysis
Immutep (ASX: IMM) has achieved a significant milestone, announcing 50% patient enrolment in its global Phase III TACTI-004 trial for first-line non-small ce
Immutep delivers major breakthrough with 59.6% response rate in lung cancer trial
Late-stage biotechnology specialist Immutep (ASX: IMM) has achieved significant improvement in response rates compared to historical controls in a trial evaluating its first-line non-small cell lung cancer (NSCLC) treatment candidate. The assessment of eftilagimod alpha (efti) with Keytruda and chemotherapy has achieved high response rates in the multi-centre INSIGHT-003 trial, an investigator-initiated study conducted by […]
